The Delaware Supreme Court has reversed the Court of Chancery’s decision to award PharmAthene Inc. half of the profits from a smallpox vaccine it was developing with Siga Technologies Inc.
The high court held that Vice Chancellor Donald F. Parsons Jr. should have awarded damages based on both parties entering a Type II preliminary agreement and not under the theory of promissory estoppel.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
